RTW INVESTMENTS, LP Buys Ultragenyx Pharmaceutical Inc (RARE) -- Shares Look 44% Undervalued on GF Value
RTW INVESTMENTS, LP significantly increased its stake in Ultragenyx Pharmaceutical Inc (RARE) by acquiring over 4.1 million shares, bringing its total holdings to 7.90% of the company. Despite an immediate 24.14% drop in stock price post-transaction, RTW's move highlights its long-term conviction in the rare disease therapeutics space. Ultragenyx, a biopharmaceutical company focusing on rare genetic diseases, shows strong growth potential (Growth Rank 9/10) but faces financial challenges, trading as a "Possible Value Trap" according to GuruFocus.
Ultragenyx scores FDA approval for gene therapy made at Bedford facility
Ultragenyx has received FDA approval for a new gene therapy that targets the root cause of glycogen storage disease type Ia. The therapy is manufactured at the company's facilities in Bedford, Massachusetts. Ultragenyx has a significant operational presence in Bedford, Somerville, and Woburn.
Citigroup Raises Ultragenyx Pharmaceutical (NASDAQ:RARE) Price Target to $58.00
Citigroup has raised its price target for Ultragenyx Pharmaceutical (NASDAQ:RARE) to $58.00 from $45.00, maintaining a "buy" rating and suggesting a nearly 129% upside. This follows positive sentiment around the FDA approval of GENGLYCOS, Ultragenyx’s fifth approved product, which analysts believe will create significant long-term revenue. Despite a recent stock dip, the company beat quarterly earnings and revenue estimates.
Ultragenyx Gene Therapy Becomes First FDA-Approved Treatment for Ultra-Rare Disease
Ultragenyx Pharmaceutical's gene therapy, Genglycos, has received accelerated FDA approval as the first treatment for glycogen storage disease type Ia (GSDIa). This one-time treatment addresses the root cause of the ultra-rare inherited enzyme deficiency, which previously required patients to consume raw cornstarch frequently. The approval, Ultragenyx's first for a gene therapy, was based on a Phase 3 study showing significant reductions in nighttime cornstarch consumption.
FDA Grants Accelerated Approval to Ultragenyx's Genglycos, First Gene Therapy for Glycogen Storage Disease Type Ia
The FDA has granted accelerated approval to Ultragenyx's Genglycos (pariglasgene brecaparvovec-opnr), a one-time AAV8 gene therapy, for patients aged eight and older with glycogen storage disease type Ia (GSDIa). This marks the first approved treatment targeting the underlying genetic cause of GSDIa, aiming to reduce cornstarch dependence. The approval was based on a study showing a significant reduction in daily cornstarch intake, though further trials are required to confirm long-term clinical benefits.
Ultragenyx Lands Genglycos Approval And Sets Its Sights On A PRV Double
Ultragenyx has secured approval for Genglycos, a significant milestone for the company. This approval positions Ultragenyx to potentially achieve a "PRV Double," indicating their strategic focus on leveraging regulatory successes. The news highlights the company's progress in the rare diseases sector.
Ultragenyx's new therapy targets patients with a rare genetic disease. It costs $2.7 million.
Ultragenyx has received FDA approval for its new $2.7 million gene therapy, which targets a rare genetic disease. This therapy is the eighth treatment from a Bay Area company to be approved this year and originated from a $151 million buyout by Ultragenyx in 2017.
RARE Stock Gains on FDA Nod for Rare Disease Gene Therapy Genglycos
Ultragenyx Pharmaceutical (RARE) shares are rising following FDA approval for Genglycos (DTX-401), an AAV8 gene therapy for glycogen storage disease type Ia (GSDIa). This marks Ultragenyx's first gene therapy approval and its fifth overall FDA approval, with Genglycos designed to reduce daily cornstarch intake in GSDIa patients. The approval is based on Phase III data showing significant reduction in cornstarch requirements and expands Ultragenyx's portfolio of rare disease treatments.
Ultragenyx Nabs FDA Nod for First Gene Therapy
Ultragenyx Pharmaceutical has received accelerated FDA approval for Genglycos (pariglasgene brecaparvovec-opnr, or DTX401), its first gene therapy, to treat Glycogen Storage Disease Type Ia (GSDIa). This marks the fifth FDA approval for Ultragenyx and the first-ever approved treatment for the ultra-rare genetic metabolic disorder. The approval, based on Phase 3 study data, has caused Ultragenyx shares to rise, with analysts projecting significant peak sales for the drug.
Canaccord raises Ultragenyx stock price target on FDA approval
Canaccord has increased its price target for Ultragenyx Pharma (NASDAQ:RARE) to $83 from $81, maintaining a Buy rating after the FDA approved the company's gene therapy, Genglycos, for glycogen storage disease type Ia. The drug, priced at $2.7 million, received accelerated approval ahead of its PDUFA date. Despite the company currently being unprofitable, analysts maintain a strong buy consensus, and InvestingPro suggests the stock is undervalued.
Ultragenyx Wins FDA Approval for GENGLYCOS, Its First Gene Therapy
Ultragenyx Pharmaceutical has received FDA accelerated approval for GENGLYCOS (DTX401), its first gene therapy, for patients aged 8 and older with Glycogen Storage Disease Type 1A (GSD1A) who lack AAV8 antibodies. The therapy aims to reduce reliance on frequent cornstarch dosing by enabling the liver to produce glucose. GENGLYCOS is expected to launch in the U.S. within 30-60 days with a wholesale price of $2.7 million per patient, though the company will delay revenue guidance until reimbursement and market demand become clearer.
Eagle Health Investments LP Acquires Shares of 884,121 Ultragenyx Pharmaceutical Inc. $RARE
Eagle Health Investments LP has acquired 884,121 shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the second quarter, making it the fund's ninth-largest position. Other institutional investors like BlackRock Inc. and Vanguard Group Inc. also significantly modified their holdings in the biopharmaceutical company. Ultragenyx Pharmaceutical has a "Moderate Buy" consensus rating from analysts, with an average price target of $57.82.
Ultragenyx receives FDA accelerated approval for gene therapy in GSDIa
Ultragenyx Pharmaceutical Inc. announced FDA accelerated approval for GENGLYCOS (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients aged eight and older with glycogen storage disease type Ia (GSDIa). The approval is based on Phase 3 study results showing a significant reduction in cornstarch requirements. As a condition of approval, Ultragenyx will provide two years of safety and efficacy data from an open-label commercial treatment program involving 70 patients.
Ultragenyx wins accelerated approval of gene therapy for glycogen storage disease
Ultragenyx Pharmaceutical (RARE) received accelerated FDA approval for its gene therapy, Genglycos (pariglasgene brecaparvovec), to treat glycogen storage disease type Ia (GSDIa) in patients aged eight and older. This condition affects approximately 1,500-2,500 individuals in the US and 6,000-8,000 globally. The approval marks a significant step for the company in addressing this rare genetic disorder.
Ultragenyx Announces U.S. FDA Approval of GENGLYCOS™ Gene Therapy, the First-Ever FDA-Approved Treatment Designed to Treat the Underlying Cause of Glycogen Storage Disease Type Ia (GSDIa)
Ultragenyx Pharmaceutical Inc. has received accelerated FDA approval for GENGLYCOS™ (pariglasgene brecaparvovec-opnr), a gene therapy for adult and pediatric patients eight years and older with glycogen storage disease type Ia (GSDIa). This marks the first-ever FDA-approved treatment targeting the underlying cause of GSDIa, aiming to reduce reliance on cornstarch and mitigate life-threatening hypoglycemia. The approval is based on positive Phase 3 data showing reduced cornstarch requirements, and Ultragenyx will provide patient support and long-term monitoring as part of the accelerated approval requirements.
Ultragenyx (RARE) Stock Could Stay Fully Priced On Setrusumab Regulatory Talks
Ultragenyx Pharmaceutical (RARE) stock has seen a sharp retreat, yet current valuations suggest it's not a clear bargain, trading at a premium to its fair P/S ratio despite being below industry averages. The stock's future hinges on the success and regulatory outcomes of its setrusumab program for osteogenesis imperfecta. Investors are currently factoring in optimism for future revenue, indicating the stock is mildly overvalued based on its fundamentals.
Bank of America Corp DE Has $21.93 Million Stock Position in Ultragenyx Pharmaceutical Inc. $RARE
Bank of America Corp DE significantly reduced its stake in Ultragenyx Pharmaceutical Inc. by 13.8% in Q1, selling 167,382 shares but still retaining over a million shares valued at $21.9 million. Despite this, institutional investors collectively own a substantial 97.67% of the company, and analysts maintain a "Moderate Buy" consensus rating with an average price target of $57.82. Ultragenyx also outperformed Q1 earnings expectations, reporting a smaller loss per share and increased revenue year-over-year.
RARE Stock Clocks Two Consecutive Days Of Losses Ahead Of Weekend FDA Decision On Gene Therapy
Ultragenyx Pharmaceutical (RARE) stock experienced two consecutive days of losses as it approaches a critical FDA decision on its gene therapy, DTX401, for von Gierke disease. The FDA is expected to rule by August 23, with an approval potentially marking a significant shift for Ultragenyx into gene therapies and adding a new growth driver. However, there's a possibility of delay, echoing a recent FDA decision for another company, given that the target date falls on a Sunday.
Ultragenyx Pharmaceutical Inc. Revenue Breakdown – NASDAQ:RARE
This article provides a breakdown of Ultragenyx Pharmaceutical Inc.'s (NASDAQ: RARE) revenue. Last year, the company generated $673.00 million USD, with its Novel Products segment being the top contributor at $673.00 million USD. Geographically, North America was the largest contributor, accounting for $377.00 million USD.
Ultragenyx (RARE): RTW Investments and Roderick Wong report 7.9% stake
RTW Investments, LP and Roderick Wong, M.D. have reported a beneficial ownership of 7.9% in Ultragenyx Pharmaceutical Inc., totaling 7,796,895 shares. This disclosure, made via a Schedule 13G filing, indicates shared voting and dispositive power over these shares, which are held by funds advised by RTW Investments. The percentage is based on 98,489,224 shares outstanding as of May 1, 2026.
Ultragenyx awaits two FDA decisions that could boost its stock to $32 from $27.
Ultragenyx Pharmaceutical is awaiting two crucial FDA decisions that could significantly impact its stock price, potentially raising it from $27 to $32 per share. The decisions involve gene therapy DTX401 for glycogen storage disease type Ia, with an 80% approval chance, and UX111, with a 65% chance. The market currently undervalues the probability of at least one approval, making these upcoming decisions key catalysts despite risks like manufacturing issues and financing needs.
Ultragenyx Pharmaceutical Inc. Stock 12‑Month Price Target Cut to $52, Implies 97% Upside
Ultragenyx Pharmaceutical Inc.'s average 12-month price target has been slightly reduced to $52 from $52.84 by 18 analysts. This new target implies a potential upside of approximately 97% based on the August 13th closing price. The consensus analyst rating remains a "Buy" from 19 covering analysts.
Ultragenyx Stock Looks Undervalued Ahead Of Two FDA Decisions (NASDAQ:RARE)
Ultragenyx Pharmaceutical (RARE) is considered undervalued with a "soft Buy" rating and a probability-weighted fair value of approximately $32 per share, against its current price near $27. The company is anticipating two crucial FDA decisions soon: one for DTX401 on August 23rd and another for UX111 on September 19th. With existing products projected to generate $730–$760 million in 2026 revenue, the market currently underestimates the likelihood of at least one of these approvals.
Ultragenyx (RARE): AQR Capital discloses 6.56M-share, 6.66% ownership stake
AQR Capital Management, LLC and AQR Capital Management Holdings, LLC have reported a passive ownership stake in Ultragenyx Pharmaceutical Inc. They beneficially own 6,560,809 shares, which constitutes 6.66% of Ultragenyx’s common stock. The filing, a SCHEDULE 13G, indicates shared voting power over 6,398,809 shares and shared dispositive power over all 6,560,809 shares, with no sole control by AQR over these holdings.
Assenagon Asset Management S.A. Sells 2,136,807 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Assenagon Asset Management S.A. significantly reduced its stake in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) by 94.6% in the second quarter, selling over 2.1 million shares. Despite this large sale, other institutional investors still own a substantial 97.67% of the company. Ultragenyx recently reported better-than-expected quarterly earnings and revenue, and analysts maintain a "Moderate Buy" consensus rating with an average price target significantly above its current trading price, even as longer-term earnings estimates have been adjusted downwards.
Ultragenyx reaches settlement on DOJOLVI patent litigation with Esjay Pharma
Ultragenyx Pharmaceutical Inc. has settled patent litigation with Baylor Research Institute and Esjay Pharma regarding its drug DOJOLVI. The agreement grants Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI starting January 1, 2033, with a potential extension to July 1, 2033, if pediatric exclusivity is granted. This settlement occurs as Ultragenyx faces financial challenges, despite strong revenue growth, and it also recently reported record Q2 2026 revenue.
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss
Ultragenyx Pharmaceutical (RARE) reported Q2 2026 revenue of US$214 million and a net loss of US$92 million, showing revenue growth and a narrower loss compared to the previous year. While these results slightly support the investment case for the rare disease and gene therapy company, investors' immediate focus remains on upcoming regulatory decisions for UX111 and DTX401, particularly the September 19, 2026 PDUFA date for UX111. The article highlights that despite improved quarterly metrics, the company still faces challenges with cash burn and potential financing needs, alongside a wide range of analyst opinions on its future profitability and fair value.
Ultragenyx reaches settlement on DOJOLVI patent litigation with Esjay Pharma
Ultragenyx Pharmaceutical Inc. announced a settlement agreement with Baylor Research Institute and Esjay Pharma to resolve patent litigation concerning DOJOLVI oral liquid. The settlement grants Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI starting January 1, 2033, or July 1, 2033, if pediatric exclusivity is granted. This development follows Ultragenyx reporting record second-quarter revenues and reaffirming its full-year guidance despite noted financial headwinds such as negative gross profit margins.
Ultragenyx to license generic DOJOLVI to Esjay starting Jan 1, 2033 under settlement
Ultragenyx announced a settlement with Esjay, resolving patent litigation concerning DOJOLVI. Under the agreement, Ultragenyx will grant Esjay a non-exclusive, royalty-free license to market a generic version of DOJOLVI beginning January 1, 2033, with a potential extension to July 1, 2033, pending pediatric exclusivity. Similar patent actions against other filers are ongoing, and the settlement will be submitted to the FTC and DOJ.
Ultragenyx reaches settlement on DOJOLVI patent litigation with Esjay Pharma
Ultragenyx Pharmaceutical Inc. has announced a settlement agreement with Baylor Research Institute and Esjay Pharma regarding patent litigation for DOJOLVI. Under the terms, Esjay will receive a non-exclusive, royalty-free license to market a generic version of DOJOLVI starting January 1, 2033, or July 1, 2033, if pediatric exclusivity is granted. This comes as Ultragenyx faces financial challenges, despite strong revenue growth in the last quarter and a reaffirmed full-year revenue guidance.
Ultragenyx Pharmaceutical Inc. (RARE) Investor Outlook: Nearly 100% Upside Potential According to Analyst Ratings
Ultragenyx Pharmaceutical Inc. (RARE), focused on rare genetic diseases, shows significant upside potential, with analysts setting an average target price of $52.84, nearly double its current $26.80. Despite current negative EPS and significant R&D investments, the company's robust product pipeline, strategic collaborations, and positive analyst sentiment point towards future growth in the specialized biotechnology sector. Investors are cautioned about the inherent risks in biotech but are encouraged by the long-term prospects.
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss
Ultragenyx Pharmaceutical reported increased Q2 2026 revenue of US$214 million and a narrower net loss of US$92 million, improving from the previous year. While these results offer some positive signs, the core investment focus remains on upcoming regulatory decisions for UX111 and DTX401, as well as managing persistent cash burn and potential financing needs. The FDA's acceptance of the UX111 BLA with a September 19, 2026 PDUFA date is a key near-term catalyst that could significantly impact the company's future revenue and investor sentiment.
Ultragenyx Pharmaceutical's (RARE) Buy Rating Reiterated at HC Wainwright
HC Wainwright has reiterated its "buy" rating for Ultragenyx Pharmaceutical (RARE) with a $50 price target, suggesting a 93% upside from its current stock price. This aligns with a "Moderate Buy" consensus among analysts, who project an average target of $57.82. The biopharmaceutical company recently exceeded earnings estimates, reporting a smaller adjusted loss and higher revenue than anticipated.
Sei Investments Co. Sells 61,632 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Sei Investments Co. has reduced its stake in Ultragenyx Pharmaceutical Inc. by 40.1% in the first quarter, selling 61,632 shares while retaining 92,094 shares valued at $1.93 million. Despite this, institutional ownership in Ultragenyx remains high at 97.67%, with several other major investors increasing their positions. Analysts generally maintain a "Moderate Buy" rating for the stock, with an average price target of $57.82.
How Investors Are Reacting To Ultragenyx Pharmaceutical (RARE) Q2 Revenue Gain And Narrower Net Loss
Ultragenyx Pharmaceutical (RARE) reported a Q2 2026 revenue gain of US$214 million, up from US$167 million year-over-year, and a narrower net loss of US$92 million compared to US$115 million. While these results support the investment case for its rare disease and gene therapy portfolio, the company's financial narrative remains focused on upcoming regulatory decisions for UX111 and DTX401, particularly the September 19, 2026, PDUFA date for UX111. Investors are closely watching how these developments will impact the company's cash burn, potential financing needs, and the balance between future upside and risk.
Ultragenyx Pharmaceutical (RARE) Following Q2 Results Looks Close To Fair Value
Ultragenyx Pharmaceutical (RARE) recently released its Q2 2026 results, reporting $214 million in revenue and a net loss of $92 million. While the company's shares trade at $25.91, near the most popular narrative's fair value of $26.00, a discounted cash flow model suggests a much higher value of $264.72, indicating significant model risk or opportunity. Investors are advised to review the data themselves due to mixed signals and the company's ongoing challenges with net losses and execution.
Quantinno Capital Management LP Purchases 137,758 Shares of Ultragenyx Pharmaceutical Inc. $RARE
Quantinno Capital Management LP significantly increased its stake in Ultragenyx Pharmaceutical Inc. by 276.9% in the first quarter, now owning 187,508 shares valued at $3.93 million. This comes as institutional investors and hedge funds hold a substantial 97.67% of the company, and analysts maintain a "Moderate Buy" rating with an average target price of $57.82. Despite beating quarterly earnings expectations with an adjusted loss of $0.90 per share and revenue of $214 million, Ultragenyx remains unprofitable, and some insiders have recently sold shares.
State Street Corporation (RARE) discloses 6.3% Ultragenyx ownership on Schedule 13G
State Street Corporation has disclosed a 6.3% ownership stake in Ultragenyx Pharmaceutical Inc., according to a Schedule 13G filing. The investment firm reported beneficial ownership of 6,158,766 shares, primarily through its investment management subsidiaries. While State Street holds no sole voting or dispositive power, it maintains shared voting power over 5,871,222 shares and shared dispositive power over all 6,158,766 shares.
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Rating of "Moderate Buy" by Analysts
Analysts have issued a consensus rating of "Moderate Buy" for Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), with 14 out of 18 analysts recommending the stock. The average 12-month price target is $57.82, significantly above the recent trading price of $25.82. The company recently reported better-than-expected quarterly results, exceeding revenue and EPS estimates, though it remains unprofitable.
Analysts Offer Insights on Healthcare Companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE) and Allogene Therapeutics (ALLO)
This article provides analyst ratings and price targets for three healthcare companies: Pfizer (PFE), Ultragenyx Pharmaceutical (RARE), and Allogene Therapeutics (ALLO). Citi analyst Geoff Meacham maintained a Hold rating on Pfizer, while Citi analyst Yigal Nochomovitz maintained a Buy rating on Ultragenyx Pharmaceutical. William Blair analyst Sami Corwin maintained a Buy rating on Allogene Therapeutics, highlighting significant upside potential for the latter two companies based on consensus price targets.
Ultragenyx Pharmaceutical Q2 Loss Narrows as Revenue Rises; 2026 Revenue Guidance Reaffirmed
Ultragenyx Pharmaceutical Inc. reported a narrower Q2 loss and increased revenue, surpassing FactSet estimates for both metrics. The company also reaffirmed its 2026 revenue guidance. This positive financial performance comes as the biopharmaceutical company continues to develop and commercialize treatments for rare and ultra-rare genetic diseases.
Ultragenyx Pharmaceutical Inc. Q2 2026: Revenue $214M, EPS $(0.90) — 10-Q Summary
Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 2026 results with revenue of $214M, a net loss of $92M, and diluted EPS of $(0.90), showing year-over-year improvement. Revenue growth was driven by Crysvita sales and royalties, and expanded demand for Evkeeza. The company also advanced its gene-therapy programs with accepted BLAs for DTX401 and UX111 and increased commercialization spend while implementing a restructuring to reduce costs.
Ultragenyx Pharmaceutical Q2 2026 Earnings Call Transcript
Ultragenyx Pharmaceutical reported a record quarterly revenue of $214 million for Q2 2026, driven by strong performance across its commercial products Crysvita, DOJOLVI, Evkeeza, and MEPSEVII. The company is preparing for potential FDA decisions on its first two gene therapies, DTX-401 for GSDIa and UX-111 for Sanfilippo syndrome type A, and anticipates top-line results for its Angelman syndrome Phase III ASPIRE trial in September or October. Ultragenyx reaffirmed its full-year guidance and reiterated its path to profitability in 2027, supported by continued product growth, potential gene therapy launches, expense discipline, and the potential monetization of priority review vouchers.
Ultragenyx Pharmaceutical Inc reports results for the quarter ended June 30 - Earnings Summary
Ultragenyx Pharmaceutical Inc has released its earnings summary for the quarter that ended on June 30. The article, sourced from Reuters and republished on TradingView News, provides details on the company's financial performance. To access the full report and more in-depth analysis, readers are directed to the full article on TradingView.
Earnings Flash (RARE) Ultragenyx Pharmaceutical Inc. Reports Q2 Revenue $214.0M, vs. FactSet Est of $183.1M
Ultragenyx Pharmaceutical Inc. (RARE) reported Q2 revenue of $214.0 million, significantly exceeding the FactSet estimate of $183.1 million. This financial update also noted a Q2 loss of $0.90 per share, which was better than the FactSet estimated loss of $1.22 per share. The biopharmaceutical company specializes in developing treatments for rare and ultra-rare genetic diseases, with products like Crysvita, Mepsevii, Dojolvi, and Evkeeza in its portfolio.
Ultragenyx Reports Second Quarter 2026 Financial Results and Corporate Update
Ultragenyx Pharmaceutical Inc. reported strong financial results for the second quarter of 2026, with total revenue reaching $214 million and reaffirming its full-year revenue guidance of $730 million to $760 million. The company is on track for profitability in 2027 and anticipates significant catalysts in the second half of 2026, including two PDUFA dates and pivotal data from the GTX-102 Phase 3 Aspire study for Angelman syndrome. This period is expected to broaden Ultragenyx's patient impact and ensure sustained growth.
Ultragenyx (RARE) CFO sells stock under 10b5-1 plan, keeps 96,295 shares
Ultragenyx Pharmaceutical Inc.'s Chief Financial Officer, Howard Horn, sold 4,696 shares of common stock on August 3, 2026, for $24.92 per share under a Rule 10b5-1 trading plan. Following this transaction, Mr. Horn directly holds 96,295 shares, which include shares underlying Restricted Stock Units (RSUs) that are still subject to vesting conditions. The sale was executed as an open-market or private transaction.
Ultragenyx Pharmaceutical Inc. (RARE) CLO sells 1,900 shares at $24.92
Ultragenyx Pharmaceutical Inc.'s EVP and Chief Legal Officer, Karah Herdman Parschauer, sold 1,900 shares of common stock at $24.92 per share on August 3, 2026, under a Rule 10b5-1 trading plan. Following this transaction, she directly holds 92,562 shares, including those from RSUs. The sale amounted to $47,000 and was reported in a Form 4 filing.
Guggenheim cuts Ultragenyx stock price target on trial uncertainty
Guggenheim has reduced its price target for Ultragenyx Pharma (NASDAQ:RARE) shares from $43 to $35, while maintaining a Buy rating, due to uncertainty surrounding the company's ASPIRE study readout in Q3 2026. The firm notes that an overwhelmingly positive result could significantly boost the stock, while an outright failure would likely lead to a substantial decline. Despite recent financial shortfalls reported in Q1 2026, Ultragenyx reaffirmed its full-year revenue guidance, and Cantor Fitzgerald recently raised its price target for the company, citing increased probability of success for the GTX-102 treatment.
Ultragenyx (RARE) insider Howard Horn files to sell 4,696 shares
Ultragenyx Pharmaceutical Inc. insider Howard Horn has filed a Form 144 to sell 4,696 shares of common stock, valued at approximately $117,024.32. These shares were acquired as Restricted Stock and Performance Shares on March 1, 2025. The filing also indicates previous sales by Horn on July 1, 2026, and June 1, 2026.
